-
ASCO GU On-Site Report | Prof. Xinan Sheng: A China-Developed Targeted–Immunotherapy Combination Opens a New Era of Bladder-Preserving Treatment for MIBC
The treatment landscape for muscle-invasive bladder cancer (MIBC) is undergoing profound transformation. Although cisplatin-based neoadjuvant chemotherapy remains the traditional standard of care, the pathological complete response (pCR) rate has long remained at approximately 30%–40%, and a substantial proportion of patients cannot receive cisplatin due to factors such as renal insufficiency. Consequently, more effective preoperative treatment…
-
ASCO GU On-Site Report | Prof. Zhisong He Discusses Post-Immunotherapy Challenges in Advanced Renal Cancer and the Future of Precision Combination Therapy in Prostate Cancer
At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), Chinese investigators once again made a strong impact on the international stage. Immunotherapy combined with targeted therapy has become the mainstream treatment paradigm for advanced renal cell carcinoma. However, key clinical questions remain unresolved worldwide, particularly how to optimize…
-
ASCO GU On-Site Report | Prof. Bo Dai: Multiple Studies from Our Team Presented at an International Meeting, Opening New Pathways for Prostate Cancer Diagnosis and Treatment
The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) has successfully concluded. As the premier annual academic event in the field of genitourinary oncology, the meeting brought together leading experts from around the world and showcased numerous cutting-edge studies and breakthroughs with the potential to reshape clinical practice.
-
Deep Responses Reshaping First-Line Standards | Prof. Qiang Dong Discusses the LIBERTAS China Subgroup Results Presented at ASCO GU 2026
The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) was held in San Francisco, USA, from February 26 to 28, showcasing some of the most innovative scientific advances in the field and exploring future directions in the treatment of genitourinary malignancies. In recent years, research and clinical practice in…
-
ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground
The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) was held in San Francisco, bringing together leading experts from around the world. As one of the most influential academic meetings in genitourinary oncology, the landmark studies presented each year at ASCO GU often directly shape the evolution of clinical practice…
-
JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate
In real-world clinical practice, a considerable proportion of patients with multiple myeloma (MM) are unable to tolerate autologous stem cell transplantation (ASCT) due to advanced age, comorbidities, or poor performance status, creating an urgent need for more effective therapeutic strategies. On February 27, 2026, a research paper entitled Phase II Study of BCMA Chimeric Antigen…
-
A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026
Everything that has passed is but a prelude. Reflecting on the progress made in urologic oncology in 2025, the field witnessed the release of numerous landmark study results alongside a series of high-level international conferences. These developments have significantly expanded the boundaries of knowledge and provided invaluable platforms for researchers worldwide to exchange ideas and…
-
Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025
Prostate cancer remains the most prevalent genitourinary malignancy among men worldwide. Early and accurate diagnosis is fundamental to comprehensive disease management, long-term survival improvement, and reduction of the societal burden of disease. As the pathological gold standard for prostate cancer diagnosis, biopsy continues to serve as the central arena for technological innovation and clinical investigation…
Connecting Medical Expertise through Media